NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Regemat 3D

Regemat 3D

Private
GranadaHealthcare & Life Scienceshttps://www.regemat3d.com/

Last Round

Crowdfunding

May 31, 2022

Est. Valuation

$19.47M

Total Funding Raised

$1.86M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

Regemat 3D is a biotechnology company that develops and provides customizable 3D bioprinters, bioreactors, and biomaterials for tissue engineering and regenerative medicine.

Sector

Healthcare & Life Sciences

Verticals

Biotech Equipment, Advanced Materials, Biotechnology, 3D Printing

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Hardware + Subscription, Government Contracts

AI Layer

Non-AI

Keywords

3D bioprintersbioprintingtissue engineeringregenerative medicinebioreactorsbiofabrication platformbiomaterialsbioinkstissue maturationorgan printingcustomizable bioprintersfunctional tissuescell-laden scaffoldsbioprinting softwareturnkey lab setup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Regemat 3D Comparables

Compare Regemat 3D with similar companies based on industry and business-model similarity.

Regemat 3D comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Allevi
86%
RegenHU
85%
Poietis
83%

Regemat 3D Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
CrowdfundingMay 31, 2022
CrowdfundingOct 20, 2020

Key People

Founding team and executive leadership

José Manuel Baena

President & CEO, Biofabrication And Cell Culture Lab Director

Executive Team

Regemat 3D Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 11, 69% of headcount.

  • Jul 13, 2026

    Open roles increased from 0 to 10, representing 63% of headcount.

Regemat 3D Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Regemat 3D Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Regemat 3D's valuation, stock price, and market status.

Firmographic Details

HeadquartersGranada
Employee Range16
Year Founded2015
Last FundingMay 31, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.